Neil Iyengar, MD

The panel grounds the discussion in the biology and natural history of metastatic triple-negative breast cancer, framing it as a high-proliferation subtype prone to rapid resistance, in which the first-line setting offers an important opportunity to influence outcomes. Panelists outline a biomarker-driven treatment algorithm stratified by PD-L1 status, germline BRCA status, and prior early-stage therapy, touching on immune checkpoint inhibition, PARP inhibitors, platinum-based chemotherapy, and the role of antibody-drug conjugates across lines of therapy.

Dr. Neil Iyengar continues the discussion on HER2-positive early breast cancer by exploring how the DESTINY-Breast11 findings may translate into routine clinical practice.

Dr. Neil Iyengar moderates a discussion with Dr. Alison Conlin and Dr. Kelly McCann on the design of the DESTINY-Breast11 trial and its implications for the management of HER2-positive early breast cancer.

Drs. Neil Iyengar and Kelly McCann review the phase III DESTINY-Breast11 trial, highlighting its design, patient population, and key findings demonstrating improved pathologic complete response rates with a trastuzumab deruxtecan–based neoadjuvant regimen in high-risk HER2-positive early breast cancer.

Drs Park and Iyengar discuss the evolving treatment paradigm for TNBC, the integration of metabolic health strategies, and the clinical emergence of ADCs.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, outline key future directions for antibody-drug conjugate (ADC) development in breast cancer.

Drs Nunnery and Iyengar highlight the evolving integration of GLP-1 agonists into the breast cancer treatment armamentarium.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how antibody-drug conjugates have altered the HER2-positive breast cancer treatment paradigm.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss the role of antibody-drug conjugates in the management of hormone receptor–positive breast cancer.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how the emergence of antibody-drug conjugates may impact sequencing considerations in triple-negative breast cancer.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss emerging data for TROP2-directed antibody-drug conjugates in metastatic triple-negative breast cancer.

Drs Nunnery and Iyengar discuss lifestyle and medical interventions pertinent to breast cancer survivorship.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how antibody-drug conjugates are weighed against other treatments in breast cancer care.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how antibody-drug conjugates have shifted the clinical management of various breast cancer subtypes.

Experts share top strategies for managing adverse effects in breast cancer treatment, emphasizing prevention, diet, and multidisciplinary support.

Explore effective strategies for managing skin rashes caused by PI3 kinase and AKT inhibitors, including prophylactic antihistamines and topical treatments.

Explore effective strategies for managing diabetes, including metformin use, dietary recommendations, and monitoring techniques for optimal health.

Explore effective strategies for managing diabetes, including metformin use, dietary recommendations, and monitoring techniques for optimal health.

Learn effective monitoring strategies for hyperglycemia in patients starting AKT or PI3 kinase inhibitors, including lab checks and home glucometers.

Healthcare professionals discuss strategies for managing diarrhea in patients, emphasizing symptom grading, treatment adjustments, and the impact of food on medication efficacy.

Healthcare professionals discuss strategies for managing diarrhea in patients, emphasizing symptom grading, treatment adjustments, and the impact of food on medication efficacy.

Explore effective diarrhea management strategies, including medication dosing, dietary adjustments, and proactive approaches for better patient outcomes.

Learn effective strategies for counseling patients on managing diarrhea when initiating PI3 kinase or AKT pathway inhibitors.

Explore expert insights on managing adverse events in advanced breast cancer treatments targeting the PI3K/AKT/PTEN pathway.

Explore expert insights on managing adverse events in advanced breast cancer treatments targeting the PI3K/AKT/PTEN pathway.

Breast cancer experts discuss adverse effect management when using breast cancer therapies targeting the PI3K, AKT, and mTOR pathways.